Andrew J. Wagner MD, PhD

Andrew J. Wagner, MD, PhD, is Associate Chief Medical Officer, Medical Director of Ambulatory Oncology, and Senior Physician in the Department of Medical Oncology at Dana-Farber Cancer Institute. He is a member of the Dana-Farber/Harvard Cancer Center Development Therapeutics Program and holds a faculty appointment as Assistant Professor of Medicine at Harvard Medical School.

Dr. Wagner earned his medical degree and doctorate of philosophy in biochemistry and molecular biology from the University of Chicago Pritzker School of Medicine. He completed a residency in internal medicine at Brigham and Women’s Hospital and a fellowship in hematology and oncology at Dana-Farber/Partners CancerCare. He is board-certified in medical oncology.

Dr. Wagner’s clinical interests include bone sarcomas, gastrointestinal stromal tumors (GISTs), and soft tissue sarcoma. Dr. Wagner conducts translational research and clinical studies to identify new targets and treatments for these diseases. He also has a special interest in developmental therapeutics. Dr. Wagner has led Phase I through Phase III studies of targeted agents in sarcomas and other solid tumors and has authored more than 70 peer-reviewed publications.

Dr. Wagner is actively involved with NCCN’s initiatives and currently serves as a member of the NCCN EHR Oncology Advisory Group and the NCCN EHR Scribe Workgroup.